Targeting cellular proapoptotic molecules for developing anticancer agents from marine sources

Current Drug Targets

Volumn 11, Issue 6, 2010, Pages 708-715

  Lin, Xiukun ^a   Liu, Ming ^a   Hu, Chaoxin ^a   Liao, D Joshua ^b  

^a INSTITUTE OF OCEANOLOGY   (China)

^b UNIVERSITY OF MINNESOTA   (United States)

Author keywords

Apoptosis; Cancer targets; Marine organisms; Natural products

Indexed keywords

4 [N (2 HYDROXYETHYL) N [2 (3 INDOLYL)ETHYL]AMINOMETHYL]CINNAMOHYDROXAMIC ACID; ANTINEOPLASTIC AGENT; ASCIDIDEMIN; BRYOSTATIN 1; CASPASE; CEPHALOSTATIN 1; CRYPTOPHYCIN 52; CYTOCHROME C; DEHYDRODIDEMNIN B; DIOXINODEHYDROECKOL; DOLASTATIN; ES 285; FUCOXANTHINOL; IMMUNOGLOBULIN ENHANCER BINDING PROTEIN; IRCININ; JASPINE B; LAMELLARIN D; MITOGEN ACTIVATED PROTEIN KINASE P38; NAAMIDINE A; NATURAL PRODUCT; ONNAMIDE A; PALMITIC ACID; PORPHYRAN; PROTEIN BAX; PROTEIN BCL 2; SOMOCYSTINAMIDE A; SPISULOSINE; STRESS ACTIVATED PROTEIN KINASE; THEOPEDERIN B; TRABECTEDIN; UNCLASSIFIED DRUG; UNINDEXED DRUG;

ANTINEOPLASTIC ACTIVITY; APOPTOSIS; ARTICLE; DOWN REGULATION; DRUG MECHANISM; ENZYME ACTIVATION; ENZYME RELEASE; MARINE SPECIES; NONHUMAN; SIGNAL TRANSDUCTION;

ANIMALS; APOPTOSIS; BIOLOGICAL PRODUCTS; HUMANS; NEOPLASMS; OCEANS AND SEAS;

EID: 77953485046     PISSN: 13894501     EISSN: None     Source Type: Journal    
DOI: 10.2174/138945010791170824     Document Type: Article

References (121)

1. Degterev A, Boyce M, Yuan J. A decade of caspases. Oncogene 2003; 22: 8543-67.
2. Thompson CB. Apoptosis in the pathogenesis and treatment of disease. Science 1995; 267: 1456-62.
3. Rowinsky EK. Targeted induction of apoptosis in cancer management: the emerging role of tumor necrosis factor-related apoptosis-inducing ligand receptor activating agents. J Clin Oncol 2005; 23: 9394-407.
4. Call JA, Eckhardt SG, Camidge DR. Targeted manipulation of apoptosis in cancer treatment. Lancet Oncol 2008; 9: 1002-11.
5. Iannolo G, Conticello C, Memeo L, De Maria R. Apoptosis in normal and cancer stem cells. Crit Rev Oncol Hematol 2008; 66: 42-51.
6. Burz C, Berindan-Neagoe I, Balacescu O, Irimie A. Apoptosis in cancer: Key molecular signaling pathways and therapy targets. Acta Oncol 2009; 9: 1-11.
7. Fulda S, Pervaiz S. Apoptosis signaling in cancer stem cells. Int J Biochem Cell Biol 2010: 42: 31-38.
8. Ghobrial IM, Witzig TE, Adjei AA. Targeting apoptosis pathways in cancer therapy. CA Cancer J Clin 2005; 55: 178-94.
9. Eberle J, Fecker LF, Forschner T, Ulrich C, Rowert-Huber J, Stockfleth E. Apoptosis pathways as promising targets for skin cancer therapy. Br J Dermatol 2007; 156: 18-24.
10. Ziegler DS, Kung AL. Therapeutic targeting of apoptosis pathways in cancer. Curr Opin Oncol 2008; 20: 97-103.
11. Qiao L, Wong BC. Targeting apoptosis as an approach for gastrointestinal cancer therapy. Drug Resist Updat 2009; 12: 55-64.
12. Reed JC. Mechanisms of apoptosis. Am J Pathol 2000; 157: 1415-30.
13. Oliver L, Vallette FM. The role of caspases in cell death and differentiation. Drug Resist Updat 2005; 8: 163-70.
14. Abe K, Kurakin A, Mohseni-Maybodi M, Kay B, Khosravi-Far R. The complexity of TNF-related apoptosis-inducing ligand. Ann N Y Acad Sci 2000; 926: 52-63.
15. Ozoren N, El-Deiry WS. Cell surface Death Receptor signaling in normal and cancer cells. Semin Cancer Biol 2003; 13: 135-47.
16. Peter ME, Krammer PH. The CD95 (APO-1/Fas) DISC and beyond. Cell Death Differ 2003; 10: 26-35.
17. Thorburn A. Death receptor-induced cell killing. Cell Signal 2004; 16: 139-44.
18. Kroemer G. Mitochondrial control of apoptosis: an introduction. Biochem Biophys Res Commun 2003; 304: 433-5.
19. Gupta S, Kass GE, Szegezdi E, Joseph B. The mitochondrial death pathway: A promising therapeutic target in diseases. J Cell Mol Med 2009; 13: 1004-33.
20. Tan G, Gyllenhaal C, Soejarto DD. Biodiversity as a source of anticancer drugs. Curr Drug Targets 2006; 7: 265-77.
21. Kinghorn AD, Chin YW, Swanson SM. Discovery of natural product anticancer agents from biodiverse organisms. Curr Opin Drug Discov Devel 2009; 12: 189-96.
22. Mayer AM, Hamann MT. Marine pharmacology in 2001--2002: marine compounds with anthelmintic, antibacterial, anticoagulant, antidiabetic, antifungal, anti-inflammatory, antimalarial, antiplatelet, antiprotozoal, antituberculosis, and antiviral activities; affecting the cardiovascular, immune and nervous systems and other miscellaneous mechanisms of action. Comp Biochem Physiol C Toxicol Pharmacol 2005; 140: 265-86.
23. Mayer AM, Gustafson KR. Marine pharmacology in 2003-2004: anti-tumour and cytotoxic compounds. Eur J Cancer 2006; 42: 2241-70.
24. Mayer AM, Gustafson KR. Marine pharmacology in 2005-2006: antitumour and cytotoxic compounds. Eur J Cancer 2008; 44: 2357-87.
25. Adrian TE. Novel marine-derived anti-cancer agents. Curr Pharm Des 2007; 13: 3417-26.
26. Gulder TA, Moore BS. Chasing the treasures of the sea-bacterial marine natural products. Curr Opin Microbiol 2009; 12: 252-60. Current Drug Targets, 2010, Vol. 11, No. 6 713
27. Molinski TF, Dalisay DS, Lievens SL, Saludes JP. Drug development from marine natural products. Nat Rev Drug Discov 2009; 8: 69-85.
28. Singh R, Sharma M, Joshi P, Rawat DS. Clinical status of anti-cancer agents derived from marine sources. Anticancer Agents Med Chem 2008; 8: 603-17.
29. Yip KW, Reed JC. Bcl-2 family proteins and cancer. Oncogene 2008; 27: 6398-406.
30. Okun I, Balakin KV, Tkachenko SE, Ivachtchenko AV. Caspase activity modulators as anticancer agents. Anticancer Agents Med Chem 2008; 8: 322-41.
31. Ghavami S, Hashemi M, Ande SR, et al. Apoptosis and cancer: mutations within caspase genes. J Med Genet 2009; 46: 497-510.
32. Kang MH, Reynolds CP. Bcl-2 inhibitors: targeting mitochondrial apoptotic pathways in cancer therapy. Clin Cancer Res 2009; 15: 1126-32.
33. Wong WW, Puthalakath H. Bcl-2 family proteins: the sentinels of the mitochondrial apoptosis pathway. IUBMB Life 2008; 60: 390-7.
34. Mutter R, Wills M. Chemistry and clinical biology of the bryostatins. Bioorg Med Chem 2000; 8: 1841-60.
35. Lu Z, Hornia A, Jiang YW, Zang Q, Ohno S, Foster DA. Tumor promotion by depleting cells of protein kinase C delta. Mol Cell Biol 1997; 17: 3418-28.
36. Choi SH, Hyman T, Blumberg PM. Differential effect of bryostatin 1 and phorbol 12-myristate 13-acetate on HOP-92 cell proliferation is mediated by down-regulation of protein kinase Cdelta. Cancer Res 2006; 66: 7261-9.
37. Wang H, Mohammad RM, Werdell J, Shekhar PV. p53 and protein kinase C independent induction of growth arrest and apoptosis by bryostatin 1 in a highly metastatic mammary epithelial cell line: In vitro versus in vivo activity. Int J Mol Med 1998; 1: 915-23.
38. Wall NR, Mohammad RM, Al-Katib AM. Bax:Bcl-2 ratio modulation by bryostatin 1 and novel antitubulin agents is important for susceptibility to drug induced apoptosis in the human early pre-B acute lymphoblastic leukemia cell line. Reh Leuk Res 1999; 23: 881-8.
39. Wall NR, Mohammad RM, Reddy KB, Al-Katib AM. Bryostatin 1 induces ubiquitination and proteasome degradation of Bcl-2 in the human acute lymphoblastic leukemia cell line. Reh Int J Mol Med 2000; 5: 165-71.
40. de Arruda M, Cocchiaro CA, Nelson CM, et al. LU103793 (NSC D-669356): a synthetic peptide that interacts with microtubules and inhibits mitosis. Cancer Res 1995; 55: 3085-92.
41. Maki A, Diwakaran H, Redman B, et al. The bcl-2 and p53 oncoproteins can be modulated by bryostatin 1 and dolastatins in human diffuse large cell lymphoma. Anticancer Drugs 1995; 6: 392-7.
42. Konishi I, Hosokawa M, Sashima T, Kobayashi H, Miyashita K. Halocynthiaxanthin and fucoxanthinol isolated from Halocynthia roretzi induce apoptosis in human leukemia, breast and colon cancer cells. Comp Biochem Physiol C Toxicol Pharmacol 2006; 142: 53-9.
43. Dhanasekaran DN, Reddy EP. JNK signaling in apoptosis. Oncogene 2008; 27: 6245-51.
44. Wagner EF, Nebreda AR. Signal integration by JNK and p38 MAPK pathways in cancer development. Nat Rev Cancer 2009; 9: 537-49.
45. Urdiales JL, Morata P, Nunez De Castro I, Sanchez-Jimenez F. Antiproliferative effect of dehydrodidemnin B (DDB), a depsipeptide isolated from Mediterranean tunicates. Cancer Lett 1996; 102: 31-7.
46. Garcia-Fernandez LF, Losada A, Alcaide V, et al. Aplidin induces the mitochondrial apoptotic pathway via oxidative stress-mediated JNK and p38 activation and protein kinase C delta. Oncogene 2002; 21: 7533-44.
47. Cuadrado A, Garcia-Fernandez LF, Gonzalez L, et al. Aplidin induces apoptosis in human cancer cells via glutathione depletion and sustained activation of the epidermal growth factor receptor, Src, JNK, and p38 MAPK. J Biol Chem 2003; 278: 241-50.
48. Gonzalez-Santiago L, Suarez Y, Zarich N, et al. Aplidin induces JNK-dependent apoptosis in human breast cancer cells via alteration of glutathione homeostasis, Rac1 GTPase activation, and MKP-1 phosphatase downregulation. Cell Death Differ 2006; 13: 1968-81.
49. Broggini M, Marchini SV, Galliera E, et al. Aplidine, a new anticancer agent of marine origin, inhibits vascular endothelial growth factor (VEGF) secretion and blocks VEGF-VEGFR-1 (flt-1) autocrine loop in human leukemia cells MOLT-4. Leukemia 2003; 17: 52-9.
50. Taraboletti G, Poli M, Dossi R, et al. Antiangiogenic activity of aplidine, a new agent of marine origin. Br J Cancer 2004; 90: 2418-24.
51. Faivre S, Chieze S, Delbaldo C, et al. Phase I and pharmacokinetic study of aplidine, a new marine cyclodepsipeptide in patients with advanced malignancies. J Clin Oncol 2005; 23: 7871-80.
52. Maroun JA, Belanger K, Seymour L, et al. Phase I study of Aplidine in a dailyx5 one-hour infusion every 3 weeks in patients with solid tumors refractory to standard therapy. A National Cancer Institute of Canada Clinical Trials Group study: NCIC CTG IND 115. Ann Oncol 2006; 17: 1371-8.
53. Reid JM, Walker DL, Ames MM. Preclinical pharmacology of ecteinascidin 729, a marine natural product with potent antitumor activity. Cancer Chemother Pharmacol 1996; 38: 329-34.
54. Takebayashi Y, Pourquier P, Zimonjic DB, et al. Antiproliferative activity of ecteinascidin 743 is dependent upon transcription-coupled nucleotide-excision repair. Nat Med 2001; 7: 961-6.
55. Friedman D, Hu Z, Kolb EA, Gorfajn B, Scotto KW. Ecteinascidin-743 inhibits activated but not constitutive transcription. Cancer Res 2002; 62: 3377-81.
56. Gajate C, An F, Mollinedo F. Differential cytostatic and apoptotic effects of ecteinascidin-743 in cancer cells. Transcription-dependent cell cycle arrest and transcription-independent JNK and mitochondrial mediated apoptosis. J Biol Chem 2002; 277: 41580-9.
57. Lee KH, Nishimura S, Matsunaga S, Fusetani N, Horinouchi S, Yoshida M. Inhibition of protein synthesis and activation of stress-activated protein kinases by onnamide A and theopederin B, antitumor marine natural products. Cancer Sci 2005; 96: 357-64.
58. Dassonneville L, Wattez N, Baldeyrou B, et al. Inhibition of topoisomerase II by the marine alkaloid ascididemin and induction of apoptosis in leukemia cells. Biochem Pharmacol 2000; 60: 527-37.
59. Matsumoto SS, Biggs J, Copp BR, Holden JA, Barrows LR. Mechanism of ascididemin-induced cytotoxicity. Chem Res Toxicol 2003; 16: 113-22.
60. Dirsch VM, Kirschke SO, Estermeier M, Steffan B, Vollmar AM. Apoptosis signaling triggered by the marine alkaloid ascididemin is routed via caspase-2 and JNK to mitochondria. Oncogene 2004; 23: 1586-93.
61. Faircloth G, Cuevas C. Kahalalide F and ES285: potent anticancer agents from marine molluscs. Prog Mol Subcell Biol 2006; 43: 363-79.
62. Salcedo M, Cuevas C, Alonso JL, et al. The marine sphingolipid-derived compound ES 285 triggers an atypical cell death pathway. Apoptosis 2007; 12: 395-409.
63. LaBarbera DV, Modzelewska K, Glazar AI, et al. The marine alkaloid naamidine A promotes caspase-dependent apoptosis in tumor cells. Anticancer Drugs 2009; 20: 425-36.
64. Choi HJ, Choi YH, Yee SB, Im E, Jung JH, Kim ND. Ircinin-1 induces cell cycle arrest and apoptosis in SK-MEL-2 human melanoma cells. Mol Carcinog 2005; 44: 162-73.
65. Kwon MJ, Nam TJ. Porphyran induces apoptosis related signal pathway in AGS gastric cancer cell lines. Life Sci 2006; 79: 1956-62.
66. Scorrano L. Opening the doors to cytochrome c: changes in mitochondrial shape and apoptosis. Int J Biochem Cell Biol 2009; 41: 1875-83.
67. Ledgerwood EC, Morison IM. Targeting the apoptosome for cancer therapy. Clin Cancer Res 2009; 15: 420-4.
68. Atadja P, Hsu M, Kwon P, Trogani N, Bhalla K, Remiszewski S. Molecular and cellular basis for the anti-proliferative effects of the HDAC inhibitor LAQ824. Novartis Found Symp 2004; 259:249-66; discussion 66-8, 85-8.
69. Wang S, Yan-Neale Y, Cai R, Alimov I, Cohen D. Activation of mitochondrial pathway is crucial for tumor selective induction of apoptosis by LAQ824. Cell Cycle 2006; 5: 1662-8.
70. Facompre M, Tardy C, Bal-Mahieu C, et al. Lamellarin D: a novel potent inhibitor of topoisomerase I. Cancer Res 2003; 63: 7392-9.
71. Marco E, Laine W, Tardy C, et al. Molecular determinants of topoisomerase I poisoning by lamellarins: comparison with Lin et al. camptothecin and structure-activity relationships. J Med Chem 2005; 48: 3796-807.
72. Kluza J, Gallego MA, Loyens A, et al. Cancer cell mitochondria are direct proapoptotic targets for the marine antitumor drug lamellarin D. Cancer Res 2006; 66: 3177-87.
73. Dirsch VM, Muller IM, Eichhorst ST, et al. Cephalostatin 1 selectively triggers the release of Smac/DIABLO and subsequent apoptosis that is characterized by an increased density of the mitochondrial matrix. Cancer Res 2003; 63: 8869-76.
74. Muller IM, Dirsch VM, Rudy A, Lopez-Anton N, Pettit GR, Vollmar AM. Cephalostatin 1 inactivates Bcl-2 by hyperphosphorylation independent of M-phase arrest and DNA damage. Mol Pharmacol 2005; 67: 1684-9.
75. Lopez-Anton N, Rudy A, Barth N, et al. The marine product cephalostatin 1 activates an endoplasmic reticulum stress-specific and apoptosome-independent apoptotic signaling pathway. J Biol Chem 2006; 281: 33078-86.
76. Cioca DP, Kitano K. Induction of apoptosis and CD10/neutral endopeptidase expression by jaspamide in HL-60 line cells. Cell Mol Life Sci 2002; 59: 1377-87.
77. Drew L, Fine RL, Do TN, Douglas GP, Petrylak DP. The novel antimicrotubule agent cryptophycin 52 (LY355703) induces apoptosis via multiple pathways in human prostate cancer cells. Clin Cancer Res 2002; 8: 3922-32.
78. Choi HJ, Bae SJ, Kim ND, Jung JH, Choi YH. Induction of apoptosis by dideoxypetrosynol A, a polyacetylene from the sponge Petrosia sp., in human skin melanoma cells. Int J Mol Med 2004; 14: 1091-6.
79. Salma Y, Lafont E, Therville N, et al. The natural marine anhydrophytosphingosine, Jaspine B, induces apoptosis in melanoma cells by interfering with ceramide metabolism. Biochem Pharmacol 2009; 78: 477-85.
80. Wrasidlo W, Mielgo A, Torres VA, et al. The marine lipopeptide somocystinamide A triggers apoptosis via caspase 8. Proc Natl Acad Sci USA 2008; 105: 2313-8.
81. Harada H, Yamashita U, Kurihara H, Fukushi E, Kawabata J, Kamei Y. Antitumor activity of palmitic acid found as a selective cytotoxic substance in a marine red alga. Anticancer Res 2002; 22: 2587-90.
82. Almaguel FG, Liu JW, Pacheco FJ, Casiano CA, De Leon M. Activation and reversal of lipotoxicity in PC12 and rat cortical cells following exposure to palmitic acid. J Neurosci Res 2009; 87: 1207-18.
83. Tas SW, Vervoordeldonk MJ, Tak PP. Gene therapy targeting nuclear factor-kappaB: towards clinical application in inflammatory diseases and cancer. Curr Gene Ther 2009; 9: 160-70.
84. Yu Y, Wan Y, Huang C. The biological functions of NF-kappaB1 (p50) and its potential as an anti-cancer target. Curr Cancer Drug Targets 2009; 9: 566-71.
85. Kong CS, Kim JA, Yoon NY, Kim SK. Induction of apoptosis by phloroglucinol derivative from Ecklonia Cava in MCF-7 human breast cancer cells. Food Chem Toxicol 2009; 47: 1653-8.
86. Roll DM, Ireland CM, Lu HSM, Clardy J. Fascaplysin, an Unusual antimicrobial pigment from the marine sponge Fascaplysinopsis sp. J Org Chem 1988; 53: 3276-8.
87. Kirsch G, Kong GM, Wright AD, Kaminsky R. A new bioactive sesterterpene and antiplasmodial alkaloids from the marine sponge hyrtios cf. erecta. J Nat Prod 2000; 63: 825-9.
88. Soni R, Muller L, Furet P, et al. Inhibition of cyclin-dependent kinase 4 (Cdk4) by fascaplysin, a marine natural product. Biochem Biophys Res Commun 2000; 275: 877-84.
89. Segraves NL, Robinson SJ, Garcia D, et al. Comparison of fascaplysin and related alkaloids: a study of structures, cytotoxicities, and sources. J Nat Prod 2004; 67: 783-92.
90. Charan RD, McKee TC, Boyd MR. Cytotoxic alkaloids from the marine sponge Thorectandra sp. Nat Prod Res 2004; 18: 225-9.
91. Subramanian B, Nakeff A, Tenney K, Crews P, Gunatilaka L, Valeriote F. A new paradigm for the development of anticancer agents from natural products. J Exp Ther Oncol 2006; 5: 195-204.
92. Hormann A, Chaudhuri B, Fretz H. DNA binding properties of the marine sponge pigment fascaplysin. Bioorg Med Chem 2001; 9: 917-21.
93. Lin J, Yan XJ, Chen HM. Fascaplysin, a selective CDK4 inhibitor, exhibit anti-angiogenic activity in vitro and in vivo. Cancer Chemother Pharmacol 2007; 59: 439-45.
94. Zheng YL, Lu XL, Lin J, et al. Direct effects of fascaplysin on human umbilical vein endothelial cells attributing the anti-angiogenesis activity. Biomed Pharmacother 2009. (doi:10.1016/j.biopha.2009.04.046)
95. Aubry C, Wilson AJ, Emmerson D, et al. Fascaplysin-inspired diindolyls as selective inhibitors of CDK4/cyclin D1. Bioorg Med Chem 2009; 17: 6073-84.
96. Jenkins PR, Wilson J, Emmerson D, et al. Design, synthesis and biological evaluation of new tryptamine and tetrahydro-beta-carboline-based selective inhibitors of CDK4. Bioorg Med Chem 2008; 16: 7728-39.
97. Garcia MD, Wilson AJ, Emmerson DP, Jenkins PR, Mahale S, Chaudhuri B. Synthesis, crystal structure and biological activity of beta-carboline based selective CDK4-cyclin D1 inhibitors. Org Biomol Chem 2006; 4: 4478-84.
98. Mahale S, Aubry C, Jenkins PR, Marechal JD, Sutcliffe MJ, Chaudhuri B. Inhibition of cancer cell growth by cyclin dependent kinase 4 inhibitors synthesized based on the structure of fascaplysin. Bioorg Chem 2006; 34: 287-97.
99. Garcia MD, Wilson AJ, Emmerson DP, Jenkins PR. Regioselective photo-oxidation of 1-benzyl-4,9-dihydro-3H-beta-carbolines. Chem Commun (Camb) 2006; 28: 2586-8.
100. Mahale S, Aubry C, James Wilson A, et al. CA224, a non-planar analogue of fascaplysin, inhibits Cdk4 but not Cdk2 and arrests cells at G0/G1 inhibiting pRB phosphorylation. Bioorg Med Chem Lett 2006; 16: 4272-8.
101. Aubry C, Wilson AJ, Jenkins PR, et al. Design, synthesis and biological activity of new CDK4-specific inhibitors, based on fascaplysin. Org Biomol Chem 2006; 4: 787-801.
102. Aubry C, Jenkins PR, Mahale S, Chaudhuri B, Marechal JD, Sutcliffe MJ. New fascaplysin-based CDK4-specific inhibitors: design, synthesis and biological activity. Chem Commun (Camb) 2004; 7: 1696-7.
103. Lu XL, Zheng YL, Chen HM, Yan XJ, Wang F, Xu WF. Anti-proliferation of human cervical cancer HeLa cell line by fascaplysin through apoptosis induction. Yao Xue Xue Bao 2009; 44: 980-6. (in Chinese).
104. Crews CM, Collins JL, Lane WS, Snapper ML, Schreiber SL. GTP-dependent binding of the antiproliferative agent didemnin to elongation factor 1 alpha. J Biol Chem 1994; 269: 15411-4.
105. Vera MD, Joullie MM. Natural products as probes of cell biology: 20 years of didemnin research. Med Res Rev 2002; 22: 102-45.
106. Johnson KL, Lawen A. Rapamycin inhibits didemnin B-induced apoptosis in human HL-60 cells: evidence for the possible involvement of FK506-binding protein 25. Immunol Cell Biol 1999; 77: 242-8.
107. Bowman EJ, Gustafson KR, Bowman BJ, Boyd MR. Identification of a new chondropsin class of antitumor compound that selectively inhibits V-ATPases. J Biol Chem 2003; 278: 44147-52.
108. Chevallier C, Laprevote O, Bignon J, Debitus C, Guenard D, Sevenet T. Isolation of cytotoxic chondropsins, macrolide lactams from the New-Caledonian marine sponge Psammoclemma sp. and electrospray ion trap multiple stage MS study of these macrolides. Nat Prod Res 2004; 18: 479-84.
109. Burres NS, Clement JJ. Antitumor activity and mechanism of action of the novel marine natural products mycalamide-A and -B and onnamide. Cancer Res 1989; 49: 2935-40.
110. Hood KA, West LM, Northcote PT, Berridge MV, Miller JH. Induction of apoptosis by the marine sponge (Mycale) metabolites, mycalamide A and pateamine. Apoptosis 2001; 6: 207-19.
111. Gurel G, Blaha G, Steitz TA, Moore PB. The structures of Triacetyloleandomycin and Mycalamide A bound to the large ribosomal subunit of Haloarcula marismortui. Antimicrob Agents Chemother 2009; 53: 5010-4
112. Hood KA, Backstrom BT, West LM, Northcote PT, Berridge MV, Miller JH. The novel cytotoxic sponge metabolite peloruside A, structurally similar to bryostatin-1, has unique bioactivity independent of protein kinase C. Anticancer Drug Des 2001; 16: 155-66.
113. Hood KA, West LM, Rouwe B, et al. Peloruside A, a novel antimitotic agent with paclitaxel-like microtubule-stabilizing activity. Cancer Res 2002; 62: 3356-60.
114. Miller JH, Rouwe B, Gaitanos TN, et al. Peloruside A enhances apoptosis in H-ras-transformed cells and is cytotoxic to proliferating T cells. Apoptosis 2004; 9: 785-96.
115. Tong Y, Zhang X, Tian F, et al. Philinopside A, a novel marine-derived compound possessing dual anti-angiogenic and anti-tumor effects. Int J Cancer 2005; 114: 843-53.
116. Aoki S, Cho SH, Ono M, et al. Bastadin 6, a spongean brominated tyrosine derivative, inhibits tumor angiogenesis by inducing selective apoptosis to endothelial cells. Anticancer Drugs 2006; 17: 269-78.
117. Hwang Y, Rowley D, Rhodes D, Gertsch J, Fenical W, Bushman F. Mechanism of inhibition of a poxvirus topoisomerase by the marine natural product sansalvamide A. Mol Pharmacol 1999; 55: 1049-53.
118. Pan PS, Vasko RC, Lapera SA, et al. A comprehensive study of Sansalvamide A derivatives: The structure-activity relationships of 78 derivatives in two pancreatic cancer cell lines. Bioorg Med Chem 2009; 17: 5806-25.
119. Esposito G, Aiello A, Carbonelli S, Menna M, Fattorusso E, Iuvone T. Mechanism of cytotoxicity of turbinamide in vitro. Anticancer Res 2002; 22: 2827-31.
120. Wei SY, Li M, Tang SA, et al. Induction of apoptosis accompanying with G(1) phase arrest and microtubule disassembly in human hepatoma cells by jaspolide B, a new isomalabaricane-type triterpene. Cancer Lett 2008: 262: 114-22.
121. Ning X, Zhao J, Zhang Y, et al. A novel anti-tumor protein extracted from Meretrix meretrix Linnaeus induces cell death by increasing cell permeability and inhibiting tubulin polymerization. Int J Oncol 2009; 35: 805-12.